hVIVO (OPORF) Total Liabilities : $55.90 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is hVIVO Total Liabilities?

hVIVO's Total Liabilities for the quarter that ended in Dec. 2024 was $55.90 Mil.

hVIVO's quarterly Total Liabilities increased from Dec. 2023 ($61.90 Mil) to Jun. 2024 ($62.70 Mil) but then declined from Jun. 2024 ($62.70 Mil) to Dec. 2024 ($55.90 Mil).

hVIVO's annual Total Liabilities increased from Dec. 2022 ($37.96 Mil) to Dec. 2023 ($61.90 Mil) but then declined from Dec. 2023 ($61.90 Mil) to Dec. 2024 ($55.90 Mil).

hVIVO Total Liabilities Historical Data

The historical data trend for hVIVO's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

hVIVO Total Liabilities Chart

hVIVO Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

35.28

28.72

37.96

61.90

55.90

hVIVO Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial															37.96	37.79	61.90	62.70	55.90

hVIVO Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

hVIVO's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	40.348	+	(13.137	+	2.416
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	55.90

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	112.381	-	56.479
	=	55.90

hVIVO's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	40.348	+	(13.137	+	2.416
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	55.90

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	112.381	-	56.479
	=	55.90

hVIVO Total Liabilities Related Terms

Thank you for viewing the detailed overview of hVIVO's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

hVIVO Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » hVIVO PLC (OTCPK:OPORF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ORPH:UK HVO:UK CRO:Germany

Address

42, New Road, Queen Mary Bioenterprises Innovation Centre, London, GBR, E1 2AX

Website

https://www.hvivo.com

hVIVO PLC is a European-focused, rare, and orphan drug consulting services platform. The principal activity of the Group is that of a rapidly growing specialist CRO pharmaceutical services company, which involves the testing of vaccines and antivirals using human-challenge clinical trials. The group is also engaged in Venn Life Sciences' Clinical Research Division, providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.

hVIVO Headlines

From GuruFocus

Open Orphan plc Announces �3m COVID-19 Challenge Virus Manufacturing Contract

By Business Wire Business Wire • 05-10-2021

Half Year 2024 hVIVO PLC Investor Presentation Transcript

By GuruFocus Research • 09-11-2024

Half Year 2023 hVIVO PLC Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Ethics Approval Granted for Open Orphan's COVID-19 Human Challenge Study Model

By Business Wire Business Wire • 02-17-2021

Full Year 2023 hVIVO PLC Analyst Briefing Transcript

By GuruFocus Research • 04-12-2024